Goodwill and Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2016

Goodwill and Intangible Assets

Schedule of weighted-average life, original cost, accumulated amortization and net book value by major class

	Weighted-Average			Accumulated
	Life (Years)	Original Cost		Amortization		Net Book Value
	(in thousands)
Definite-lived intangible assets
Product rights	12	$	27,134	$	23,124	$	4,010
Patents	10		293		115		178
Trademarks	11		15		15		—
Land-use rights	39		2,540		304		2,236
Acquired ANDAs(1)	*		4,000		—		4,000
Other intangible assets	1		575		521		54
Subtotal	12		34,557		24,079		10,478
Indefinite-lived intangible assets
Trademark	*		29,225		—		29,225
Goodwill
Finished pharmaceutical products	*		4,321		—		4,321
Subtotal	*		33,546		—		33,546
As of March 31, 2016	*	$	68,103	$	24,079	$	44,024

	Weighted-Average			Accumulated
	Life (Years)	Original Cost		Amortization		Net Book Value
	(in thousands)
Definite-lived intangible assets
Product rights	12	$	27,134	$	22,679	$	4,455
Patents	10		293		107		186
Trademarks	11		15		15		—
Land-use rights	39		2,540		288		2,252
Other intangible assets	1		590		533		57
Subtotal	12		30,572		23,622		6,950
Indefinite-lived intangible assets
Trademark	*		29,225		—		29,225
Goodwill
Finished pharmaceutical products	*		3,726		—		3,726
Subtotal	*		32,951		—		32,951
As of December 31, 2015	*	$	63,523	$	23,622	$	39,901

*Intangible assets with indefinite lives have an indeterminable average life.

(1)In March 2016, the Company acquired fourteen ANDAs representing eleven different injectable chemical entities from Hikma Pharmaceuticals PLC for $4.0 million.  As a result, the accounting and determination of the life of the intangible asset has yet to be determined. (See note 3).

Schedule of changes in carrying amounts of goodwill

	March 31,		December 31,
	2016		2015
	(in thousands)
Beginning balance	$	3,726	$	4,467
Goodwill related to acquisition of business		444		—
Currency translation and other adjustments		151		(741)
Ending balance	$	4,321	$	3,726